Short answer: compounded semaglutide is not FDA-approved, so the FDA has not reviewed it for safety, effectiveness, or quality. The FDA has received adverse-event reports and dosing-error reports involving compounded semaglutide. The risk depends heavily on where it comes from: a licensed pharmacy filling a clinician's prescription is very different from a "research use only" website.
This article is educational and is not medical advice. Whether any treatment is appropriate for you is decided by a licensed clinician after reviewing your health history.
Is compounded semaglutide FDA-approved?
No. FDA-approved semaglutide products (Wegovy, Ozempic, Rybelsus) went through FDA review of their safety, effectiveness, and manufacturing quality. A compounded version is prepared by a pharmacy for an individual patient and does not go through that review (FDA).
What safety problems has the FDA reported?
From the FDA's page on unapproved GLP-1 drugs:
- Adverse-event reports. As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide. The FDA notes it cannot always confirm that a product caused a reported event.
- Dosing errors. Some patients measured and injected the wrong amount, in some cases leading to hospitalization (FDA dosing-error alert). Compounded vials are often measured in units on a syringe, which is easy to get wrong.
- Salt forms. Semaglutide sodium and semaglutide acetate are different active ingredients from the one in approved drugs. The FDA says they should not be used to compound semaglutide.
What are the side effects?
Compounded semaglutide has the same active ingredient as the approved drug, so the side effects described on the FDA label are the ones to know. The most common are gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach pain. Serious risks include pancreatitis and gallbladder problems. See GLP-1 side effects and MedlinePlus: semaglutide.
Who should not take it?
Semaglutide carries a boxed warning based on thyroid C-cell tumors seen in rodent studies. People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use it, and it is not used during pregnancy. See who should not take a GLP-1.
How do I lower the risks?
- Get a prescription from a licensed clinician who reviews your health history first.
- Make sure a licensed pharmacy fills it. You can check a pharmacy's license with your state board of pharmacy.
- Never buy "research use only" semaglutide. It is not made for people. See prescription vs. research-use-only peptides.
- Follow the measuring instructions exactly. Ask your clinician or pharmacist if anything is unclear before your first dose.
- Report side effects to your clinician and to FDA MedWatch.
Can compounded semaglutide still be prescribed?
Since the FDA declared the semaglutide shortage resolved in February 2025, compounded semaglutide may generally be prepared only when a licensed clinician documents a specific clinical reason the approved product is not suitable for that patient. Cost and convenience are not clinical reasons. See the rules for compounded GLP-1s.
How ElliotMeds handles it
At ElliotMeds, a licensed U.S. clinician reviews every request before anything is prescribed, and approved treatments are filled by a licensed U.S. compounding pharmacy. Every treatment page states that compounded medications are not FDA-approved. If you're not approved, you receive a full refund. How ElliotMeds works.
Sources
Every program includes a clinician chart review. When prescribed, treatments are filled by a licensed U.S. pharmacy.
Important note
Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing. A licensed clinician determines whether a treatment is appropriate based on the information provided.